vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $18.3M, roughly 1.4× ROCKWELL MEDICAL, INC.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -49.7%, a 46.6% gap on every dollar of revenue. On growth, BCB BANCORP INC posted the faster year-over-year revenue change (13.1% vs -25.6%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $2.2M). Over the past eight quarters, BCB BANCORP INC's revenue compounded faster (1.8% CAGR vs -10.1%).
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
BCBP vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $18.3M |
| Net Profit | $-12.0M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | -71.9% | -2.2% |
| Net Margin | -49.7% | -3.0% |
| Revenue YoY | 13.1% | -25.6% |
| Net Profit YoY | -467.6% | 26.7% |
| EPS (diluted) | $-0.73 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $18.3M | ||
| Q3 25 | $26.5M | $15.9M | ||
| Q2 25 | $25.2M | $16.1M | ||
| Q1 25 | $23.8M | $18.9M | ||
| Q4 24 | $23.1M | $24.7M | ||
| Q3 24 | $26.2M | $28.3M | ||
| Q2 24 | $20.4M | $25.8M | ||
| Q1 24 | $25.3M | $22.7M |
| Q4 25 | $-12.0M | $-554.0K | ||
| Q3 25 | $4.3M | $-1.8M | ||
| Q2 25 | $3.6M | $-1.5M | ||
| Q1 25 | $-8.3M | $-1.5M | ||
| Q4 24 | $3.3M | $-756.0K | ||
| Q3 24 | $6.7M | $1.7M | ||
| Q2 24 | $2.8M | $343.0K | ||
| Q1 24 | $5.9M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -71.9% | -2.2% | ||
| Q3 25 | 21.9% | -9.9% | ||
| Q2 25 | 19.9% | -8.4% | ||
| Q1 25 | -49.2% | -7.2% | ||
| Q4 24 | 19.9% | -2.1% | ||
| Q3 24 | 35.7% | 6.8% | ||
| Q2 24 | 19.5% | 2.0% | ||
| Q1 24 | 33.0% | -5.8% |
| Q4 25 | -49.7% | -3.0% | ||
| Q3 25 | 16.1% | -11.0% | ||
| Q2 25 | 14.2% | -9.3% | ||
| Q1 25 | -35.0% | -8.0% | ||
| Q4 24 | 14.1% | -3.1% | ||
| Q3 24 | 25.5% | 5.9% | ||
| Q2 24 | 13.8% | 1.3% | ||
| Q1 24 | 23.2% | -7.6% |
| Q4 25 | $-0.73 | $-0.01 | ||
| Q3 25 | $0.22 | $-0.05 | ||
| Q2 25 | $0.18 | $-0.05 | ||
| Q1 25 | $-0.51 | $-0.04 | ||
| Q4 24 | $0.17 | $-0.02 | ||
| Q3 24 | $0.36 | $0.04 | ||
| Q2 24 | $0.14 | $0.01 | ||
| Q1 24 | $0.32 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $37.0M |
| Total Assets | $3.3B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $304.3M | $37.0M | ||
| Q3 25 | $318.5M | $37.0M | ||
| Q2 25 | $315.7M | $30.4M | ||
| Q1 25 | $314.7M | $31.5M | ||
| Q4 24 | $323.9M | $32.6M | ||
| Q3 24 | $328.1M | $29.1M | ||
| Q2 24 | $320.7M | $23.5M | ||
| Q1 24 | $320.1M | $20.6M |
| Q4 25 | $3.3B | $57.1M | ||
| Q3 25 | $3.4B | $57.5M | ||
| Q2 25 | $3.4B | $52.6M | ||
| Q1 25 | $3.5B | $54.0M | ||
| Q4 24 | $3.6B | $59.2M | ||
| Q3 24 | $3.6B | $57.1M | ||
| Q2 24 | $3.8B | $53.0M | ||
| Q1 24 | $3.8B | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $2.3M |
| Free Cash FlowOCF − Capex | $34.9M | $2.2M |
| FCF MarginFCF / Revenue | 133.3% | 12.0% |
| Capex IntensityCapex / Revenue | 4.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $2.3M | ||
| Q3 25 | $8.7M | $-1.3M | ||
| Q2 25 | $10.3M | $1.8M | ||
| Q1 25 | $5.0M | $-3.5M | ||
| Q4 24 | $67.7M | $865.0K | ||
| Q3 24 | $43.5M | $4.3M | ||
| Q2 24 | $8.1M | $1.4M | ||
| Q1 24 | $8.3M | $-2.4M |
| Q4 25 | $34.9M | $2.2M | ||
| Q3 25 | $8.5M | $-1.5M | ||
| Q2 25 | $10.2M | $1.7M | ||
| Q1 25 | $4.7M | $-3.5M | ||
| Q4 24 | $66.5M | $470.0K | ||
| Q3 24 | $43.4M | $4.1M | ||
| Q2 24 | $8.1M | $1.2M | ||
| Q1 24 | $8.1M | $-2.5M |
| Q4 25 | 133.3% | 12.0% | ||
| Q3 25 | 32.0% | -9.6% | ||
| Q2 25 | 40.4% | 10.5% | ||
| Q1 25 | 19.8% | -18.8% | ||
| Q4 24 | 287.5% | 1.9% | ||
| Q3 24 | 166.0% | 14.4% | ||
| Q2 24 | 39.6% | 4.5% | ||
| Q1 24 | 32.3% | -11.1% |
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 1.1% | 1.4% | ||
| Q2 25 | 0.6% | 1.0% | ||
| Q1 25 | 1.2% | 0.3% | ||
| Q4 24 | 5.3% | 1.6% | ||
| Q3 24 | 0.3% | 0.7% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 0.6% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | 2.57× | ||
| Q2 24 | 2.88× | 4.20× | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
